|

Trastuzumab Rezetecan Clinical Trials

7 actively recruiting trials

▲ +3 trials since June 2026

Pipeline

Phase 2: 6Phase 4: 1

Top Sponsors

  • Peking Union Medical College Hospital2
  • Sun Yat-sen University1
  • Sheng Zhang1
  • Peking University People's Hospital1
  • Henan Cancer Hospital1

Indications

  • Cancer7
  • Breast Cancer4
  • Biliary Tract Neoplasms Immunotherapy2
  • HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis1
  • Advanced Solid Tumor Cancer1

Other7 trials

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer
Phase 2
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
Phase 2
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Phase 2
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
Phase 4
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Phase 2
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
Phase 2
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.